EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Incidence and outcomes of kidney replacement therapy for end-stage kidney disease due to primary glomerular disease in Europe: findings from the ERA Registry

Samar Abd ElHafeez iD, Anneke Kramer iD, Mustafa Arici, Miha Arnol, Anders Åsberg, Samira Bell, Julie Belliere, Carmen Díaz Corte, Gema Fernández Fresnedo, Marc Hemmelder, Line Heylen iD, Kristine Hommel und 17 weitere

Nephrology Dialysis Transplantation · 30.08.2024 · 39 (9) · 1449-1460

DOI: 10.1093/ndt/gfae034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 07.02.2024. Verfasst von Samar Abd ElHafeez und 28 weiteren Autor:innen. Beteiligte Einrichtung: ERA Registry, Department of Medical Informatics, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Kidney Failure, Chronic, Registries, Renal Replacement Therapy. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Renal Association, Comunidad de Madrid, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Primary glomerular disease (PGD) is a major cause of end-stage kidney disease (ESKD) leading to kidney replacement therapy (KRT). We aimed to describe incidence (trends) in individuals starting KRT for ESKD due to PGD and to examine their survival and causes of death.

Methods

We used data from the European Renal Association (ERA) Registry on 69 854 patients who started KRT for ESKD due to PGD between 2000 and 2019. ERA primary renal disease codes were used to define six PGD subgroups. We examined age and sex standardized incidence, trend of the incidence and survival.

Results

The standardized incidence of KRT for ESKD due to PGD was 16.6 per million population (pmp), ranging from 8.6 pmp in Serbia to 20.0 pmp in France. Immunoglobulin A nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) had the highest incidences, of 4.6 pmp and 2.6 pmp, respectively. Histologically non-examined PGDs represented over 50% of cases in Serbia, Bosnia and Herzegovina, and Romania and were also common in Greece, Estonia, Belgium and Sweden. The incidence declined from 18.6 pmp in 2000 to 14.5 pmp in 2013, after which it stabilized. All PGD subgroups had 5-year survival probabilities above 50%, with crescentic glomerulonephritis having the highest risk of death [adjusted hazard ratio 1.8 (95% confidence interval 1.6–1.9)] compared with IgAN. Cardiovascular disease was the most common cause of death (33.9%).

Conclusion

The incidence of KRT for ESKD due to PGD showed large differences between countries and was highest and increasing for IgAN and FSGS. Lack of kidney biopsy facilities in some countries may have affected accurate assignment of the cause of ESKD. The recognition of the incidence and outcomes of KRT among different PGD subgroups may contribute to a more individualized patient care approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney Failure, ChronicRegistriesRenal Replacement TherapyHumansIncidenceFemaleMaleEuropeMiddle AgedAdultAgedSurvival RateYoung AdultAdolescentGlomerulonephritis

Stichwörter der Autor:innen

dialysisepidemiologykidney replacement therapyoutcomeprimary glomerular disease

Autor:innen und Institutionen

  • ERA Registry, Department of Medical Informatics, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.
  • Epidemiology Department, High Institute of Public Health, Alexandria University, Alexandria, Egypt.
  • Amsterdam Public Health, Quality of Care and Ageing & Later Life, Amsterdam, The Netherlands.
  • Department of Nephrology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
  • Department of Nephrology, University Medical Centre Ljubljana, Ljubljana, Slovenia.
  • Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.

ORCID-Profile: Samar Abd ElHafeez, Anneke Kramer, Line Heylen, Julia Kerschbaum, Mårten Segelmark, Kitty J Jager, Alberto Ortiz

Förderung

  • European Renal Association
  • Comunidad de Madrid
  • Instituto de Salud Carlos III
  • European Commission
  • FEDER
  • COST

Zitieren

APA

Abd ElHafeez, S., Kramer, A., Arici, M., Arnol, M., Åsberg, A., Bell, S., Belliere, J., Corte, C. D., Fresnedo, G. F., Hemmelder, M., Heylen, L., Hommel, K., Kerschbaum, J., Naumović, R., Nitsch, D., Santamaria, R., Finne, P., Palsson, R., Pippias, M., …, & Stel, V. S. (2024). Incidence and outcomes of kidney replacement therapy for end-stage kidney disease due to primary glomerular disease in Europe: findings from the ERA Registry. Nephrology Dialysis Transplantation, 39(9), 1449-1460. https://doi.org/10.1093/ndt/gfae034

Vancouver

Abd ElHafeez S, Kramer A, Arici M, Arnol M, Åsberg A, Bell S, et al. Incidence and outcomes of kidney replacement therapy for end-stage kidney disease due to primary glomerular disease in Europe: findings from the ERA Registry. Nephrology Dialysis Transplantation. 2024;39(9):1449-1460. doi:10.1093/ndt/gfae034

BibTeX
@article{AbdElHafeez2024,
  author = {Abd ElHafeez, Samar and Kramer, Anneke and Arici, Mustafa and Arnol, Miha and Åsberg, Anders and Bell, Samira and Belliere, Julie and Corte, Carmen Díaz and Fresnedo, Gema Fernández and Hemmelder, Marc and Heylen, Line and Hommel, Kristine and Kerschbaum, Julia and Naumović, Radomir and Nitsch, Dorothea and Santamaria, Rafael and Finne, Patrik and Palsson, Runolfur and Pippias, Maria and Resic, Halima and Rosenberg, Mai and de Pablos, Carmen Santiuste and Segelmark, Mårten and Sørensen, Søren Schwartz and Soler, Maria Jose and Vidal, Enrico and Jager, Kitty J and Ortiz, Alberto and Stel, Vianda S},
  title = {Incidence and outcomes of kidney replacement therapy for end-stage kidney disease due to primary glomerular disease in Europe: findings from the ERA Registry},
  journal = {Nephrology Dialysis Transplantation},
  year = {2024},
  volume = {39},
  number = {9},
  pages = {1449--1460},
  doi = {10.1093/ndt/gfae034}
}
Kostenlos starten →